Prostate Study NRG GU003
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT).
Post-prostatectomy RT has traditionally been delivered in conventional fractionation that can take as long as 6 to 8 weeks to deliver. The proposed study explores an alternative RT dose-fractionation schedule that exploits the radiobiological properties of prostate cancer to shorten overall treatment time called hypofractionation. Patients will be randomized (1:1) to either conventional radiation or hypofractionated radiation.
The potential advantages of hypofractionation are: 1) increased convenience to patients because of fewer treatment days, 2) reduced cost to patients because of reduced travel expenses and copays, 3) improved resource utilization for physicians because of the fewer number of treatments per patient and overall, 4) and consequently reduced cost to society.
In prostate cancer specifically, hypofractionation has the added potential advantage of not increasing toxicity (primary endpoint of Phase II) compared to standard fractionation, while delivering a higher biological dose and therefore increase efficacy (primary endpoint for Phase III).
Stephanie Porenta, RN BSN CCRC: 425.467.3986, Stephanie.Porenta@overlakehospital.org
Tina Fortney, RN BSN CCRC: 425.688.5407, Tina.Fortney@overlakehospital.org
Clinical Trial Categories
Overlake Medical Center
1035 116th Ave. NE
Bellevue, WA 98004